Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

REGN1979 shows good activity in pretreated aggressive B-NHL

Key clinical point: REGN1979 showed strong activity against relapsed/refractory aggressive B-cell non-Hodgkin lymphomas.

Major finding: The overall response rate among patients with follicular lymphoma was 95%.

Study details: A phase 1, dose-escalation study of 110 patients with aggressive-histology B-cell lymphomas.

Disclosures: The study is supported by Regeneron Pharmaceuticals. Dr. Bannerji reported research funding, travel support, and consulting fees from Regeneron and others.


Bannerji R et al. ASH 2019, Abstract 762.